

Ibai Goicoechea

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4947093/ibai-goicoechea-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

22
papers

490
citations

11
h-index

22
g-index

25
ext. papers

669
ext. citations

7.3
avg, IF

3
L-index

#	Paper	IF	Citations
22	New Concepts in Cancer Biomarkers: Circulating miRNAs in Liquid Biopsies. <i>International Journal of Molecular Sciences</i> , 2016 , 17,	6.3	162
21	The circulating transcriptome as a source of non-invasive cancer biomarkers: concepts and controversies of non-coding and coding RNA in body fluids. <i>Journal of Cellular and Molecular Medicine</i> , 2015 , 19, 2307-23	5.6	64
20	Targeted next-generation sequencing and non-coding RNA expression analysis of clear cell papillary renal cell carcinoma suggests distinct pathological mechanisms from other renal tumour subtypes. <i>Journal of Pathology</i> , 2014 , 232, 32-42	9.4	39
19	Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma. <i>Blood</i> , 2020 , 136, 199-209	2.2	31
18	The Circulating Transcriptome as a Source of Biomarkers for Melanoma. <i>Cancers</i> , 2019 , 11,	6.6	28
17	Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma. <i>Blood</i> , 2021 , 137, 49-60	2.2	28
16	MGMT Expression Predicts PARP-Mediated Resistance to Temozolomide. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 1236-46	6.1	26
15	Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination. <i>Leukemia</i> , 2020 , 34, 589-603	10.7	19
14	Noncoding RNA Expression and Targeted Next-Generation Sequencing Distinguish Tubulocystic Renal Cell Carcinoma (TC-RCC) from Other Renal Neoplasms. <i>Journal of Molecular Diagnostics</i> , 2018 , 20, 34-45	5.1	16
13	Mutational profiling can identify laryngeal dysplasia at risk of progression to invasive carcinoma. <i>Scientific Reports</i> , 2018 , 8, 6613	4.9	13
12	Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2020 , 135, 2375-2387	2.2	11
11	Characterization of herpes simplex virus 1 strains as platforms for the development of oncolytic viruses against liver cancer. <i>Liver International</i> , 2011 , 31, 1542-53	7.9	10
10	The Urinary Transcriptome as a Source of Biomarkers for Prostate Cancer. <i>Cancers</i> , 2020 , 12,	6.6	8
9	Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma. <i>Leukemia</i> , 2020 , 34, 3007-3018	10.7	7
8	Preneoplastic somatic mutations including in lymphoplasmacytic lymphoma.. <i>Science Advances</i> , 2022 , 8, eabl4644	14.3	4
7	Single-Cell Characterization of the Multiple Myeloma (MM) Immune Microenvironment Identifies CD27-Negative T Cells As Potential Source of Tumor-Reactive Lymphocytes. <i>Blood</i> , 2019 , 134, 506-506	2.2	4
6	Spatial intratumoural heterogeneity in the expression of GIT1 is associated with poor prognostic outcome in oestrogen receptor positive breast cancer patients with synchronous lymph node metastases. <i>F1000Research</i> , 2017 , 6, 1606	3.6	4

5	Spatial intratumoural heterogeneity in the expression of GIT1 is associated with poor prognostic outcome in oestrogen receptor positive breast cancer patients with synchronous lymph node metastases. <i>F1000Research</i> , 2017 , 6, 1606	3.6	4
4	Aberrant Expression of MicroRNAs in B-cell Lymphomas. <i>MicroRNA (Sharjah, United Arab Emirates)</i> , 2016 , 5, 87-105	2.9	4
3	Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development. <i>Blood</i> , 2021 , 138, 1583-1589	2.2	4
2	Differential chemosensitivity to antifolate drugs between RAS and BRAF melanoma cells. <i>Molecular Cancer</i> , 2014 , 13, 154	42.1	2
1	MicroRNAs as B-cell lymphoma biomarkers. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2015 , 25	2.6	1